Article Contents
Clin Exp Pediatr > Volume 65(7); 2022 |
|
Characteristic | Phase I (n=315) (1998–2007) | Phase II (n=426) (2008–2017) | P value |
---|---|---|---|
Gestational age | 31+3 (23+0–42+1) | 30+3 (22+3–40+0) | |
<26 weeks | 40/315 (12.7) | 89/426 (20.9) | 0.004a) |
26–35 weeks | 153/315 (48.6) | 197/426 (32.9) | <0.001a) |
≥35 weeks | 122/315 (38.7) | 140/426 (32.9) | 0.099a) |
Male sex | 173/315 (54.9) | 229/426 (53.8) | 0.753a) |
Birth weight (g) | 1,468 (469–4,900) | 1,290 (282–4,125) | |
<1,500 | 160/315 (50.8) | 246/426 (57.7) | 0.060a) |
1,500–2,500 | 58/315 (18.4) | 73/426 (17.1) | 0.652a) |
≥2,500 | 97/315 (30.8) | 107/426 (25.1) | 0.087a) |
Delivery mode (cesarean section) | 191/315 (60.6) | 294/426 (69.0) | 0.018a) |
Inborn | 226/315 (71.7) | 407/426 (85.4) | <0.001a) |
Multiple gestation | 30/315 (9.5) | 174/426 (27.5) | <0.001a) |
Variable |
EOS |
LOS |
|||||||
---|---|---|---|---|---|---|---|---|---|
Phase I (n=35) (1998–2007) | Phase II (n=17) (2008–2017) | P value | OR (95% CI) | Phase I (n=324) (1998–2007) | Phase II (n=519) (2008–2017) | P value | OR (95% CI) | ||
Gram-positive bacteria | 26 (74.3) | 8 (47.1) | 0.053a) | 0.308 (0.091–1.039) | 212 (65.4) | 428 (82.5) | <0.001a) | 2.485 (1.801–3.428) | |
CoNS | 11 (31.4) | 5 (29.4) | 0.882a) | 0.909 (0.257–3.218) | 114 (35.2) | 345 (66.5) | <0.001a) | 3.652 (2.728–4.890) | |
Staphylococcus aureus | 4 (11.4) | 0 (0) | 0.290b) | - | 51 (15.7) | 57 (11.0) | 0.044a) | 0.660 (0.440–0.991) | |
Enterococcus faecalis | 0 (0) | 1 (5.9) | 0.327b) | - | 5 (1.5) | 11 (2.1) | 0.551a) | 1.381 (0.476–4.013) | |
Streptococcus agalactiae, group B | 2 (5.7) | 2 (11.8) | 0.589b) | 2.200 (0.282–17.137) | 1 (0.3) | 4 (0.8) | 0.654b) | 2.509 (0.279–22.545) | |
Othersc) | 9 (25.7) | 0 (0) | 0.023b) | - | 41 (12.7) | 11 (2.1) | <0.001a) | 0.149 (0.076–0.295) | |
Gram-negative bacteria | 9 (25.7) | 9 (52.9) | 0.053a) | 3.250 (0.962–10.978) | 112 (34.6) | 91 (17.5) | <0.001a) | 0.402 (0.292–0.555) | |
Klebsiella pneumoniae | 1 (2.9) | 2 (11.8) | 0.246b) | 4.533 (0.381–53.925) | 32 (9.9) | 29 (5.6) | 0.019a) | 0.540 (0.320–0.911) | |
Enterobacter cloacae | 4 (11.4) | 1 (5.9) | 1.000b) | 0.484 (0.050–4.702) | 18 (5.6) | 9 (1.7) | 0.002a) | 0.300 (0.133–0.676) | |
Escherichia coli | 1 (2.9) | 2 (11.8) | 0.246b) | 4.533 (0.381–53.925) | 13 (4.0) | 12 (2.3) | 0.157a) | 0.566 (0.255–1.257) | |
Burkholderia cepacia | 0 (0.0) | 1 (5.9) | 0.327b) | - | 7 (2.2) | 17 (3.3) | 0.344a) | 1.534 (0.629–3.740) | |
Pseudomonas aeruginosa | 2 (5.7) | 0 (0) | 1.000b) | - | 18 (5.6) | 3 (0.6) | <0.001a) | 0.099 (0.029–0.338) | |
Acinetobacter baumannii | 0 (0) | 2 (11.8) | 0.103b) | - | 9 (2.8) | 4 (0.8) | 0.040b) | 0.272 (0.083–0.890) | |
Serratia marcescens | 0 (0) | 0 (0) | - | 6 (1.9) | 7 (1.3) | 0.576b) | 0.725 (0.241–2.175) | ||
Enterobacter aerogenes | 1 (2.9) | 0 (0) | 1.000b) | - | 6 (1.9) | 2 (0.4) | 0.060b) | 0.205 (0.041–1.022) | |
Klebsiella oxytoca | 0 (0) | 0 (0) | - | 3 (0.9) | 5 (1.0) | 1.000b) | 1.041 (0.247–4.385) | ||
Othersd) | 0 (0) | 1 (5.9) | 0.327b) | - | 0 (0.0) | 3 (0.4) | 0.289a) | - |
Values are presented as number (%).
EOS, early-onset sepsis; LOS, late-onset sepsis; OR, odds ratio; CI, confidence interval; CoNS, coagulase-negative Staphylococcus.
c) Others: Listeria monocytogenes, Streptococcus species (except S. agalactiae), Enterococcus faecium, Bacillus species, Clostridium clostridioforme, Micrococcus species.
Microorganism | Phase I (1998–2007) | Phase II (2008–2017) | P value | OR (95% CI) |
---|---|---|---|---|
Mortality | 39/315 | 27/426 | ||
Klebsiella pneumoniae | 5/33 (15.2) | 7/31 (22.6) | 0.447a) | 1.633 (0.458–5.819) |
ESBL-producing | 2/5 (40.0) | 5/7 (71.4) | ||
Pseudomonas aeruginosa | 7/20 (35.0) | 2/3 (66.7) | 0.538b) | 3.714 (0.284–48.545) |
Staphylococcus aureus | 6/55 (10.9) | 3/57 (5.3) | 0.317b) | 0.454 (0.108–1.913) |
Staphylococcus epidermidis | 5/122 (5.0) | 3/125 (1.2) | 0.047b) | 0.234 (0.055–0.997) |
Escherichia coli | 4/14 (28.6) | 2/14 (14.3) | 0.648b) | 0.417 (0.063–2.768) |
Enterobacter cloacae | 3/22 (13.6) | 1/10 (10.0) | 1.000b) | 0.704 (0.064–7.742) |
Mortality of EOS | 7/33 (21.2) | 5/17 (29.4) | 0.728b) | 1.548 (0.407–5.887) |
Mortality of LOS | 32/282 (11.3) | 22/409 (5.4) | 0.004a) | 0.444 (0.252–0.782) |
Total mortality | 39/315 (12.4) | 27/426 (6.3) | 0.004a) | 0.479 (0.286–0.801) |
Factor | Episodes | P value | OR (95% CI) |
---|---|---|---|
GA (wk) | 0.016a) | 0.496 (0.278–0.886) | |
<37 | 50/554 (9.0) | ||
≥37 | 16/341 (4.7) | ||
Birth weight (g) | |||
<1,500 | 36/508 (7.1) | 0.706a) | 1.102 (0.666–1.823) |
≥1,500 | 30/387 (7.8) | ||
<2,500 | 47/660 (7.1) | 0.627a) | 1.147 (0.659–1.998) |
≥2,500 | 19/235 (8.1) | ||
Gram-positive bacteria | 23/674 (3.4) | <0.001 | 6.838 (4.014–11.649) |
Gram-negative bacteria | 43/221 (19.5) | ||
MRSA mortality rate | 6/66 (9.0) | ||
ESBLb) mortality rate | 9/41 (21.9) |
Microorganism | Phase I (1998–2007) | Phase II (2008–2017) | P value | OR (95% CI) |
---|---|---|---|---|
Gram-positive bacteria | ||||
Staphylococcus aureus | ||||
Penicillin | 1/52 (1.9) | 2/57 (3.5) | 1.000b) | 1.855 (0.163–21.076) |
Cefotaxime | 12/52 (23.1) | 8/12 (66.7) | 0.006b) | 6.667 (1.707–26.042) |
Oxacillin | 10/52 (19.2) | 33/57(57.9) | <0.001a) | 5.775 (2.426–13.746) |
CoNS | ||||
Penicillin | 1/114 (0.9) | 0/350(0.0) | 0.246b) | 0.991 (0.974–1.008) |
Cefotaxime | 3/105 (2.9) | 1/51 (2.0) | 1.000b) | 0.680 (0.069–6.704) |
Oxacillin | 3/114 (2.6) | 10/350(2.9) | 1.000b) | 1.088 (0.294–4.025) |
Gram-negative bacteria | ||||
Klebsiella pneumoniae | ||||
Gentamicin | 9/30 (30.0) | 26/31 (83.9) | <0.001a) | 12.133 (3.528–41.729) |
Cefotaxime | 6/30 (20.0) | 20/31 (64.5) | 0.001a) | 7.273 (2.284–23.160) |
Ceftriaxone | 6/30 (20.0) | 16/20 (80.0) | <0.001a) | 16.000 (3.889–65.830) |
Enterobacter cloacae | ||||
Gentamicin | 5/20 (25.0) | 10/10 (100.0) | <0.001a) | 0.250 (0.117–0.534) |
Cefotaxime | 5/20 (25.0) | 8/10 (80.0) | 0.007b) | 12.000 (1.885–76.376) |
Ceftriaxone | 5/20 (25.0) | 5/6 (83.3) | 0.018b) | 15.000 (1.397–161.045) |
Escherichia coli | ||||
Gentamicin | 5/14 (35.7) | 7/14 (50.0) | 0.704a) | 1.800 (0.396–8.182) |
Cefotaxime | 7/13 (53.8) | 6/14 (42.9) | 0.568a) | 0.643 (0.141–2.938) |
Ceftriaxone | 7/14 (50.0) | 2/5 (40.0) | 1.000b) | 0.667 (0.084–5.301) |